SCHEMBL2407424

SCHEMBL2407424

N#Cc1cccc(-c2ccc(N3CCC(CCN(Cc4nccs4)C(=O)O)CC3)nc2)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.43
HRH3 Q9Y5N1 5/20 0.43
DGAT1 O75907 1/20 0.41
KCNH2 Q12809 1/20 0.41
PDE4D Q08499 3/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
AOC3 Q16853 3/20 0.39
CHRM4 P08173 3/20 0.39
CETP P11597 2/20 0.38
THRB P10828 1/20 0.37
USP30 Q70CQ3 1/20 0.37
MLNR O43193 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406534 0.91 DGAT1 (0.42) HRH3DGAT1KCNH2CHRM4CETP
SCHEMBL2406228 0.89 AOC3 (0.41) DGAT1KCNH2PDE4DPDE4APDE4B
SCHEMBL2407642 0.88 CNR2 (0.44) DGAT1KCNH2PDE4DPDE4APDE4B
SCHEMBL2411687 0.84 DGAT1 (0.41) MCHR1HRH3DGAT1KCNH2AOC3
SCHEMBL2404039 0.84 DGAT1 (0.41) MCHR1HRH3DGAT1KCNH2CHRM4
SCHEMBL2408002 0.83 TRPM8 (0.41) HRH3DGAT1AOC3CHRM4
SCHEMBL2411396 0.77 CHRM4 (0.41) DGAT1KCNH2CHRM4CETPUSP30
SCHEMBL14796868 0.77 CHRM4 (0.55) DGAT1KCNH2CHRM4CETPUSP30
SCHEMBL2406077 0.73 PDE10A (0.45) MCHR1HRH3DGAT1KCNH2
SCHEMBL2431551 0.72 MCHR1 (0.39) MCHR1HRH3DGAT1KCNH2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912218-B2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-12-16 US disclosed
US-20110212963-A1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212963-A1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MET, ALK, REL MCHR1 300/4885HRH3 42/4885DGAT1 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.